Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17161979 | 1.00 | CD274 (0.89) | CD274PDCD1 | |
| SCHEMBL17161471 | 0.94 | PDCD1 (0.84) | CD274PDCD1 | |
| SCHEMBL17161474 | 0.94 | PDCD1 (0.84) | CD274PDCD1 | |
| SCHEMBL17161634 | 0.94 | PDCD1 (0.84) | CD274PDCD1 | |
| SCHEMBL17161834 | 0.94 | CD274 (1.00) | CD274PDCD1 | |
| SCHEMBL17161830 | 0.94 | CD274 (1.00) | CD274PDCD1 | |
| SCHEMBL17161976 | 0.93 | PDCD1 (0.82) | CD274PDCD1 | |
| SCHEMBL17161599 | 0.93 | PDCD1 (0.82) | CD274PDCD1 | |
| SCHEMBL17161722 | 0.93 | PDCD1 (0.82) | CD274PDCD1 | |
| SCHEMBL17161602 | 0.93 | PDCD1 (0.82) | CD274PDCD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3131876-B1 | COMPOUNDS USEFUL AS IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2018-11-07 | — | — | EP | claimed |
| US-9850225-B2 | Compounds useful as immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-12-26 | — | — | US | claimed |
| EP-3131876-A2 | COMPOUNDS USEFUL AS IMMUNOMODULATORS | Bristol-Myers Squibb Company (US) | 2017-02-22 | — | — | EP | claimed |
| WO-2015160641-A2 | COMPOUNDS USEFUL AS IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-10-22 | — | — | WO | claimed |
| US-20150291549-A1 | Compounds Useful as Immunomodulators | BRISTOL-MYERS SQUIBB COMPANY | 2015-10-15 | — | — | US | claimed |
| EP-3131876-B1 | COMPOUNDS USEFUL AS IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2018-11-07 | — | — | EP | disclosed |
| US-9850225-B2 | Compounds useful as immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-12-26 | — | — | US | disclosed |
| EP-3131876-A2 | COMPOUNDS USEFUL AS IMMUNOMODULATORS | Bristol-Myers Squibb Company (US) | 2017-02-22 | — | — | EP | disclosed |
| WO-2015160641-A2 | COMPOUNDS USEFUL AS IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-10-22 | — | — | WO | disclosed |
| US-20150291549-A1 | Compounds Useful as Immunomodulators | BRISTOL-MYERS SQUIBB COMPANY | 2015-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291549-A1 | Compounds Useful as Immunomodulators | CD74, HLA-DRB1, CD47 | CD274 52/4885PDCD1 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.